Uncategorized
Valeant announces Q3 financial results
Valeant Pharmaceuticals announced its third quarter 2016 financial results, which included total revenues of $2.48 billion, compared with $2.70 billion in the third quarter of 2015, according to a press release.The decrease of 11% was the result of decline in product sales and revenue, which was primary due to a decline in product sales revenues from existing businesses, according to the release.